Puma Biotechnology | PBYI - Selling And Administration Expenses


Puma Biotechnology reported $16.82M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Exelixis USD 139.6M 16.58M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Moderna USD 173M 135M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Takeda JPY 292B 9.21B Mar/2026
TG Therapeutics USD 73.14M 22.42M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026